- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03951298
Neurodegenerazione I-Tracking nella sindrome di Wolfram precoce (I-TRACK)
Monitoraggio internazionale della neurodegenerazione nella sindrome di Wolfram precoce
Wolfram syndrome (WFS; OMIM #222300) is a rare autosomal recessive disease clinically defined in 1938 as the combination of childhood-onset insulin dependent diabetes, optic nerve atrophy, diabetes insipidus and deafness. Based on early descriptions, neurological features were thought to appear later in the disease with death occurring in middle adulthood. Importantly, the major causative gene (WFS1) was identified in 1998. This discovery allowed researchers to determine that the WFS1 gene encodes the protein wolframin, which helps protect cells from endoplasmic reticulum (ER) stress-mediated apoptosis, potentially via intracellular calcium homeostasis. Pathogenic mutations in WFS1 can result in death or dysfunction of cells that are under high ER stress, such as insulin-producing pancreatic β cells, causing insulin dependent diabetes. In addition, knowing the causative gene has allowed researchers to identify patients by their WFS1 mutation rather than the classic set of symptoms, leading to the increasing realization that the WFS1-related phenotype (including neurologic symptoms) is much more variable than previously understood. The first iteration of this grant (HD070855 "Tracking Neurodegeneration in Early Wolfram Syndrome") contributed to this shift in understanding. In this time, the research team has built a successful annual research clinic for WFS, that has met or exceeded recruitment goals for patients and controls, validated a clinical severity rating scale for WFS, described an unexpectedly early neurophenotype of reduced balance, smell identification and ventral pons volume, identified alterations in traditional diffusion tensor imaging (DTI) metrics that suggest hypomyelination as a pervasive neuropathological feature of WFS and provided justification for the selection of two primary outcomes (visual acuity and ventral pons volume) in a newly funded clinical efficacy study in WFS (Barrett, PI).
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
In this new grant, researchers hypothesize that ER stress-related dysfunction could inhibit production of myelin during neurodevelopment in WFS, as active and developing oligodendrocytes (cells that produce myelin in the brain) are more vulnerable to ER stress than mature ones. However, standard DTI methods conflate inflammatory processes (which can also be associated with ER stress) in the extra-axonal space with metrics of axonal and myelin integrity, leading to potentially confounded measurements. The research team proposea to collect novel, validated diffusion sequences on a new state of the art MRI scanner (Siemens Prisma) and apply cutting-edge analysis approaches to measure white matter integrity throughout the brain and in the optic nerve, improving the ability to draw conclusions about axonal and myelin integrity over time. Researchers will assess WFS patients annually at our WU Wolfram Research Clinic using these methods.
Findings from this work may indicate future targets for brain-specific intervention, identify outcome measures or high-risk subgroups for clinical trials targeting neurological symptoms. These data will also greatly expand our understanding of the cross-sectional and longitudinal phenotype of WFS1-mutation related disorders, rather than classically defined Wolfram Syndrome. Such knowledge will have a significant impact on patients and families by allowing physicians to provide more accurate prognoses. Finally, forms of ER stress-mediated apoptosis have been implicated in more common neurodegenerative, endocrine and neurodevelopmental diseases, which may benefit from the insights gained here.
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
Missouri
-
St Louis, Missouri, Stati Uniti, 63110
- Washington University School of Medicine
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Age, gender and handedness-matched participants between the age of 1 day to no upper limit.
Descrizione
Wolfram Syndrome Group (WFS):
Inclusion Criteria:
-
Patient has confirmation of a WFS1 mutation OR
-
Both of the following conditions:
- diabetes mellitus requiring insulin and
- optic nerve atrophy diagnosed by a physician.
Exclusion Criteria:
- Patient is unaware of their diagnosis.
- Inability of patient or guardian to understand informed consent.
- Advanced disease that makes traveling too problematic and/or uncomfortable for the patient and/or guardian, such as the use of a ventilator or inability to walk.
Sibling Group: Biological, half and step-siblings who do not have any symptoms of WFS and/or have had genetic testing to show that they do not have WFS may participate.
Exclusion Criteria:
• Inability of participant or guardian to understand informed consent.
Proxy Group: Adult Biological parent(s), biological caregiver, or non-biological caregiver of adult and minor participants in any of the four groups.
Inclusion criteria:
• Biological or non-biological parent/caregiver (proxy) of a participant.
Exclusion Criteria:
• Proxy is unaware of the participant's diagnosis (as it applies).
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Coorti e interventi
Gruppo / Coorte |
|---|
|
Wolfram Syndrome Patients
Participant has confirmation of a WFS1 mutation OR Both of the following conditions: diabetes mellitus requiring insulin and optic nerve atrophy diagnosed by a physician. Both conditions diabetes mellitus and optic nerve atrophy had to be diagnosed at age younger than 18 years old |
|
Proxy Group
Adult Biological parent(s), biological caregiver or non-biological caregiver of adult and minor participants in the Wolfram group. These individuals report on symptoms of their family member with Wolfram. |
|
Siblings
Sibling Group: Biological, half and step-siblings who do not have any symptoms of WFS and/or have had genetic testing to show that they do not have WFS may participate. Exclusion Criteria: • Inability of participant or guardian to understand informed consent. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Regional Pons Volume
Lasso di tempo: last assessment in this longitudinal study, each participant was followed between 1 and 5 years.
|
MRI measure of pons brain volume for Wolfram and sibling groups |
last assessment in this longitudinal study, each participant was followed between 1 and 5 years.
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Disease Severity Score
Lasso di tempo: last assessment in this longitudinal study, each participant was followed between 1 and 5 years.
|
WURS physical severity score; rated by physician; range is 0 (no impairment) to 132 (most severe impairment) |
last assessment in this longitudinal study, each participant was followed between 1 and 5 years.
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Tamara G Hershey, PhD, Washington University Medical School
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Manifestazioni neurologiche
- Malattie del sistema endocrino
- Malattie del sistema nervoso
- Malattie urogenitali maschili
- Malattie renali
- Malattie urologiche
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Malattie genetiche, congenite
- Malattie metaboliche
- Disturbi del metabolismo del glucosio
- Malattie degli occhi
- Malattie Neurodegenerative
- Malattie degli occhi, ereditarie
- Anomalie congenite
- Malattie otorinolaringoiatriche
- Disturbi della vista
- Disturbi della sensibilità
- Anomalie multiple
- Malattie Eredodegenerative, Sistema Nervoso
- Malattie dell'orecchio
- Malattie del nervo ottico
- Malattie dei nervi cranici
- Malattie ipofisarie
- Disturbi sordo-ciechi
- Perdita dell'udito
- Disturbi dell'udito
- Cecità
- Atrofie ottiche, ereditarie
- Diabete mellito, tipo 1
- Malattie e anomalie congenite, ereditarie e neonatali
- Condizioni patologiche, segni e sintomi
- Malattie nutrizionali e metaboliche
- Segni e sintomi
- Diabete mellito
- Sordità
- Atrofia ottica
- Sindrome di Wolfram
- Diabete insipido
Altri numeri di identificazione dello studio
- 201808060
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .